Fda Approves Wellbutrin Xl(r) for the Prevention of Seasonal Major Depressive Episodes

by Jennifer Alinio - Date: 2007-03-25 - Word Count: 228 Share This!

The U.S. Food and Drug Administration (FDA) has approved Wellbutrin XL(R) for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD), a condition affecting about 6 percent of American adults. Wellbutrin XL is the first and only medication approved to prevent seasonal major depressive episodes.

"Seasonal affective disorder is a serious and often under-diagnosed form of depression that affects millions of people each year in the United States," said Norman E. Rosenthal, M.D., clinical professor of Psychiatry at Georgetown Medical School and medical director of Capital Clinical Research Associates. "The FDA approval of Wellbutrin XL for the prevention of seasonal major depressive episodes in adults diagnosed with SAD is exciting. For the first time, it may be possible to prevent the predictable onset of SAD with medication by beginning treatment in the autumn season, prior to experiencing depressive symptoms."

A combined analysis of three clinical trials showed that Wellbutrin XL reduces the chance of developing a seasonal major depressive episode by 44 percent.

There are so many sites devoting the attention to the promotion of this drug. DrugstoreTM.com is one of the trusted sources of this product. You can now buy soma online. Visit DrugstoreTM.com, your reputable online pharmacy, for more details.

DrugstoreTM.com Online Drug Store provides a wide range of services such as drug information, health care products and prescription medication online.

Related Tags: discount drug store, drug store pharmacy, discount pharmacies, health medicines, health product, bupropion

Jennifer Alinio is an Article Writer for DrugStoreTM.Com for details please visit,DrugStoreTM.Com Online Drugstore

Your Article Search Directory : Find in Articles

© The article above is copyrighted by it's author. You're allowed to distribute this work according to the Creative Commons Attribution-NoDerivs license.

Recent articles in this category:

Most viewed articles in this category: